Tag: Prescription Drugs
Solanezumab Does Not Slow Cognitive Decline in Preclinical Alzheimer Disease
Mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab, placebo
One-Hour Training Improves Documentation to Diagnose, Treat Tardive Dyskinesia
Implementation of training session increased proportion of patients with documented Abnormal Involuntary Movement Score
Donanemab Slows Clinical Progression in Early Alzheimer Disease
Slows clinical progression at 76 weeks for those with low/medium tau and the combined low/medium and high tau pathology population
Determinants of Overall Survival in Metastatic Uveal Melanoma Identified
Female sex, anti-CTLA‐4 therapy, and anti-PD‐1 therapy linked to better overall survival, while worse survival seen with hepatic metastases
Treatment Effect of Tofacitinib, Adalimumab Compared in RA
Modest reduction seen in DAS28-CPR at three months for those receiving TOF versus ADA, but no difference seen at nine months
Pharmacy-Level Stewardship Can Save on Immune Checkpoint Inhibitors
Strategies include dose rounding and vial sharing, as well as weight-based dosing
European Regulators Investigating Risk for Suicidal Thoughts With Popular Weight-Loss Drugs
Three case reports from Iceland spurred the review; two of the cases involved Ozempic
Stimulant Treatment for Childhood ADHD Not Linked to Substance Use
No evidence seen for link between childhood stimulant treatment and substance use during adolescence and young adulthood
Variation Seen in Dosing of Meds at Prehospital Pediatric Encounters
Lowest consistency with guidelines was seen for diazepam and lorazepam; most deviations represented an underdose
P2Y₁₂ Inhibitor Monotherapy Better Than Aspirin in Coronary Artery Disease
Reduced risk seen for composite of cardiovascular death, myocardial infarction, and stroke
